Science Sphere

Science Sphere Welcome to Science Sphere, where science comes to life!

We believe that science is more than just a subject to study; it is a way of thinking, exploring, and understanding our world. We are passionate about bringing you the latest breakthroughs, innovations, and discoveries in medical science, astronomy, and technology. From mind-bending physics to cutting-edge biotech, we strive to make science accessible, engaging, and exciting for everyone. So whether you're a scientist, student, or simply curious about the world around you, join us on this journey of discovery, and let's explore the wonders of science together!

πŸ”¬ The case for psychedelics as a superior treatment for depression has been built on a serious flaw in how clinical tria...
27/03/2026

πŸ”¬ The case for psychedelics as a superior treatment for depression has been built on a serious flaw in how clinical trials work. A new meta-analysis from UCSF, UCLA, and Imperial College London has now exposed it, and the findings are humbling even to the researchers who ran the study.

The core problem is blinding. In standard drug trials, patients don't know whether they received the real treatment or a placebo, which isolates the drug's true effect. But psychedelics make this impossible. The subjective experience is so powerful and unmistakable that virtually every participant knows they received the drug, not a dummy pill. Antidepressant trials, by contrast, can maintain genuine blinding. This creates a built-in advantage for psychedelics: patients who know they took a life-changing compound expect to feel better, and often do.

To level the playing field, the researchers compared results from eight psychedelic therapy trials against 16 open-label antidepressant trials, where participants also knew they were taking the real drug. When both groups were operating under the same conditions of "knowing," the apparent superiority of psychedelics vanished. Both groups improved by roughly 12 points on a standard depression scale.

"What I wanted to show is that even if you compare psychedelics to open-label antidepressants, psychedelics are still much better," said lead researcher BalΓ‘zs Szigeti of UCSF. "Unfortunately, what we got is the opposite."

This doesn't mean psychedelics don't work. They do. But they may not work better than a well-prescribed antidepressant when both are given a fair comparison.

πŸ“„ RESEARCH PAPER
πŸ“Œ Williams et al, "Psychedelic therapy vs antidepressants for the treatment of depression under equal unblinding conditions", JAMA Psychiatry (2026)

πŸ„ Between 40 and 60 percent of people with OCD don't respond to standard treatments. A new trial from Yale suggests a si...
27/03/2026

πŸ„ Between 40 and 60 percent of people with OCD don't respond to standard treatments. A new trial from Yale suggests a single session with psilocybin may offer something current medicine cannot: rapid, lasting relief.

Researchers enrolled 28 adults who had lived with OCD for an average of 20 years and had already failed at least two treatments. Half received a single oral dose of psilocybin, the active compound in magic mushrooms. The other half received niacin as an active placebo.

Within 48 hours, psilocybin patients showed an average drop of nearly 10 points on the standard OCD severity scale, against virtually no change in the placebo group. Around 70% of the psilocybin group reported roughly a 35% symptom reduction at one week. Crucially, those improvements were still holding at the 12-week follow-up.

The thinking is that psilocybin interrupts the rigid, repetitive neural loops that drive OCD. As David Nutt of Imperial College London put it, a psychedelic experience may break cycles of obsessive thinking in ways that SSRIs and therapy simply cannot match for speed or durability.

Caveats apply. The trial was small, and larger studies are needed to confirm efficacy and safety. But this is the strongest controlled evidence yet that psilocybin could become a real option for one of psychiatry's most treatment-resistant conditions.

Follow Science Sphere for regular scientific updates

πŸ“„ RESEARCH PAPER
πŸ“Œ Kelmendi et al, "Psilocybin for Treatment-Resistant OCD: A Randomized Controlled Trial", Yale School of Medicine (2026)

🫁 A 33-year-old man arrived at a Chicago hospital in cardiac arrest. His lungs, destroyed by a flu-triggered infection r...
27/03/2026

🫁 A 33-year-old man arrived at a Chicago hospital in cardiac arrest. His lungs, destroyed by a flu-triggered infection resistant to every antibiotic, were liquefying. His only chance was a lung transplant. But his body was too unstable and too infected to survive one.

Surgeons at Northwestern Medicine faced a brutal dilemma. The lungs had to come out to stop the infection killing him. But without lungs, a person cannot survive. Their solution was to engineer a total artificial lung (TAL) system that had never been used this way before, then remove both lungs entirely and keep the patient alive on the machine while his body recovered.

The TAL system did more than oxygenate blood. It was designed to compensate for the loss of the lungs' role in regulating blood flow through the heart, a function conventional ECMO machines don't address. To stop the empty chest cavity from destabilizing the heart, the team even placed saline-filled tissue expanders inside the chest as temporary supports.

Within 24 hours of removing the infected lungs, the patient's blood pressure stabilized and his organ function began recovering. After 48 hours, donor lungs became available. The transplant went ahead. More than two years later, he is living normally with strong lung function.

The team also performed molecular analysis of the removed lungs, finding irreversible scarring and immune destruction, the first biological proof that some ARDS patients simply cannot recover without a transplant.

πŸ“„ RESEARCH PAPER
πŸ“Œ Yan et al, "Bridge to transplant using a flow-adaptive extracorporeal total artificial lung system following bilateral pneumonectomy", Med (2026)

🧠 Getting a severe UTI or being hospitalized for a tooth infection sounds like a temporary problem. But a major new stud...
27/03/2026

🧠 Getting a severe UTI or being hospitalized for a tooth infection sounds like a temporary problem. But a major new study suggests the brain may bear the consequences for years afterward.

Researchers at the University of Helsinki analyzed nationwide health registry data from Finland covering more than 62,000 people aged 65 and older who were diagnosed with dementia between 2017 and 2020, alongside over 312,000 matched dementia-free controls. They examined every hospital-treated disease recorded in the two decades before a dementia diagnosis, identifying 29 conditions robustly linked to higher dementia risk.

Of those 29, 27 were non-infectious, involving the heart, brain, and other organs. But two that stood out independently were infections: severe cystitis (a urinary tract infection) and bacterial infections of no specific documented site. These weren't just tagging along with other known risk factors. Even after fully adjusting for all 27 non-infectious dementia-related conditions, the infection link held firm. Less than one-seventh of the excess dementia risk was explained by pre-existing diseases. The infections, on average, occurred around five to six years before dementia was diagnosed.

The picture was even more alarming for early-onset dementia, diagnosed before the age of 65. Here, five types of infection were linked to roughly doubled risk, and tooth decay (dental caries) appeared on that list alongside pneumonia and other bacterial infections. This suggests that serious oral infections severe enough to require hospital treatment may be doing something to the brain long before cognitive symptoms become visible.

The researchers suspect that the inflammation triggered by severe infections may damage the brain's blood vessels, disrupt the blood-brain barrier, and accelerate underlying cognitive decline that was already quietly progressing.

πŸ“„ RESEARCH PAPER
πŸ“Œ SipilΓ€ et al, "The role of noninfectious comorbidities in the association between severe infections and risk of dementia in Finland: A nationwide registry study", PLOS Medicine (2026)

🧬 Your fear of getting older might actually be making your body age faster at the cellular level. That's not a motivatio...
27/03/2026

🧬 Your fear of getting older might actually be making your body age faster at the cellular level. That's not a motivational poster. It's what the data is starting to show.

Researchers at the NYU School of Global Public Health analyzed blood samples and survey data from 726 women participating in the nationally representative Midlife in the United States study. They measured biological aging using two state-of-the-art epigenetic clocks: DunedinPACE, which tracks the current speed of biological aging, and GrimAge2, which estimates accumulated cellular damage over time. Epigenetic clocks work by reading chemical patterns on DNA to determine how fast the body is actually aging, independent of how many birthdays someone has had.

Women who reported higher anxiety about growing older showed measurably faster biological aging on the DunedinPACE clock. Crucially though, not all aging worries carried equal weight. Fear of declining health was the strongest driver of accelerated aging. Concerns about appearance and fertility showed no significant biological link, possibly because those anxieties tend to ease as people grow older, while health-related fears tend to stick and compound over time.

The researchers are careful to note what the study cannot yet tell us. It captures one moment in time and cannot establish direct cause and effect. When coping behaviors tied to anxiety, like smoking and alcohol use, were factored in, the association between aging anxiety and epigenetic aging lost statistical significance. That means the lifestyle habits triggered by anxiety may be doing a lot of the biological damage.

Still, the finding that psychological experiences can register at the molecular level of DNA is striking. How we feel about aging is, it turns out, not separate from the biology of aging.

πŸ“„ RESEARCH PAPER
πŸ“Œ Rodrigues et al, "Aging anxiety and epigenetic aging in a national sample of adult women in the United States", Psychoneuroendocrinology (2026)

πŸ’Š Metformin has been prescribed to hundreds of millions of people with type 2 diabetes for over 60 years. Scientists kne...
26/03/2026

πŸ’Š Metformin has been prescribed to hundreds of millions of people with type 2 diabetes for over 60 years. Scientists knew it worked. They just didn't fully know why.

Researchers at Baylor College of Medicine have now uncovered a major piece of that puzzle: the drug works directly on the brain, through a mechanism nobody had identified before. The discovery, published in Science Advances, centers on a small protein called Rap1 sitting inside a region of the brain called the ventromedial hypothalamus (VMH), a control hub for whole-body metabolism.

When metformin reaches the VMH, it effectively switches Rap1 off. That, in turn, activates a specific cluster of neurons called SF1 neurons, which then signal the body to lower blood sugar. When the team bred mice with no Rap1 in this brain region and put them on a high-fat diet, metformin completely stopped working. Other diabetes drugs like insulin and GLP-1 agonists still worked fine, showing the brain pathway is unique to metformin.

One of the most striking findings was just how sensitive the brain is compared to the liver and gut. The liver and intestines need high concentrations of the drug to respond. The brain, on the other hand, reacted to doses thousands of times smaller than what is typically given orally.

This reframes six decades of medical understanding. Metformin was never just a liver drug or a gut drug. It has been quietly acting in the brain the whole time. Researchers now plan to explore whether this same Rap1 brain pathway also explains metformin's other well-documented benefits, including slowing brain aging and its links to longer lifespan.

Human studies are still needed to confirm the mechanism, but the door is now open to far more targeted diabetes therapies.

πŸ“„ RESEARCH PAPER
πŸ“Œ Lin et al, "Low-dose metformin requires brain Rap1 for its antidiabetic action", Science Advances (2025)

πŸ”¬ WHO tells men to abstain for 2 to 7 days before giving a s***m sample for fertility treatment. A new Oxford study says...
26/03/2026

πŸ”¬ WHO tells men to abstain for 2 to 7 days before giving a s***m sample for fertility treatment. A new Oxford study says that advice may be doing more harm than good.

Researchers at the University of Oxford conducted a sweeping meta-analysis of 115 human studies covering nearly 55,000 men, combined with 56 studies across 30 non-human animal species. Their conclusion is striking: s***m sitting in storage, whether inside the male body during abstinence or inside the female reproductive tract, ages and deteriorates rapidly in a process they call post-meiotic s***m senescence.

In men, longer abstinence periods were directly linked to more DNA damage in s***m, higher oxidative stress, and measurable declines in s***m motility and viability. The damage happens because s***m cells are uniquely vulnerable. They burn through their energy reserves quickly, carry almost no protective cytoplasm, and have very little capacity to repair themselves. The longer they sit waiting, the worse they get.

Crucially, the decline in s***m quality happened regardless of how old the man was. S***m ages on its own clock, independent of the person producing it. The same deterioration pattern was observed across the animal kingdom, from fruit flies to mammals, with reduced fertilization success and poorer embryo quality as direct consequences.

The study did find one notable exception. Females, across species, appear to be better at preserving stored s***m. Their specialized storage organs seem to actively nourish and protect s***m using antioxidants, something that evolution has fine-tuned over millions of years and that researchers think could inspire better artificial s***m storage technology.

The takeaway for fertility medicine is clear: more frequent ej*******on, not extended abstinence, produces healthier s***m.

πŸ“„ RESEARCH PAPER
πŸ“Œ Sanghvi et al, "S***m storage causes s***m senescence in human and non-human animals", Proceedings of the Royal Society B (2026)

πŸ«€ Fatty liver disease affects roughly one in three adults worldwide, and right now, there is no approved drug to treat i...
26/03/2026

πŸ«€ Fatty liver disease affects roughly one in three adults worldwide, and right now, there is no approved drug to treat it. That could be about to change.

Researchers at the Hebrew University of Jerusalem have found that two non-psychoactive compounds from the cannabis plant, CBD (cannabidiol) and CBG (cannabigerol), can significantly reduce liver fat and restore metabolic health in obese mice.

Neither compound causes a high. What makes this study stand out is the mechanism the team uncovered. Instead of working through the usual cannabinoid receptors, both CBD and CBG boosted levels of phosphocreatine in liver cells, essentially acting like a backup battery to help an overworked liver cope with the stress of a high-fat diet.

On top of that, these compounds reactivated enzymes called cathepsins, which are the liver's cellular cleaning crew. This helped the organ break down and clear out harmful fats and waste that had been building up.

After four weeks on a high-fat diet, mice treated with either compound showed improved blood sugar control, lower lipid levels, and better insulin sensitivity. CBG was the stronger performer overall, outperforming CBD in reducing body fat, cutting bad LDL cholesterol, and improving insulin sensitivity.

The findings are in mice for now, and it remains to be seen whether oral CBD products would work the same way as injections. But the team has already patented the combination of CBD and CBG for metabolic disorders, and clinical trials may follow.

πŸ“„ RESEARCH PAPER
πŸ“Œ KočvarovΓ‘ et al, "Cannabidiol and cannabigerol ameliorate steatotic liver disease via phosphocreatine buffering and lysosomal restoration", British Journal of Pharmacology (2026)

Address

Melbourne, VIC

Website

Alerts

Be the first to know and let us send you an email when Science Sphere posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Science Sphere:

Shortcuts

Featured

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram